Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, controlled clinical trial to evaluate the short-term and
long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and
preserving renal function in patients with IgAN who have pre-treated (and continue to be
treated) with angiotensin II receptor blockers (ARB), compared to the corticosteroids.